A vigorous debate is occurring at the WHA in Geneva over the need for R&D cost transparency leading to availability of medicines at affordable prices. Italy has submitted a resolution that is supported by some, modified by others and opposed by others. Detailed analyses of what is happening has been provided and can be seen here
- Italy submits drug pricing transparency resolution to WHO
- Italy and 11 co-sponsors introduce transparency resolution text to WHA72
- Improving the transparency of markets for medicines, vaccines, and other health-related products and other technologies to be discussed at the 72nd session of the WHA to be held on 20-28 May 2019
- Push for drug pricing transparency strikes a nerve with industry
- Side event: Health Policy Watch: Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event
- Clinical trials: Roche and Novartis neglect their ethical responsibility in emerging countries